US-based Setpoint Medical has selected Sagentia as a development partner for its neuromodulation device indicated for chronic inflammatory disease.

The company is currently developing a bioelectronics medicine platform that includes an implanted MicroRegulator, a charger unit that charges the MicroRegulator, and an ‘RxPad’ iPad prescription application that sets the dose and frequency of the therapy.

The scientific platform is based on the inflammatory reflex, the natural mechanism the central nervous system uses toregulate the immune system.

Stimulating the vagus nerve, the MicroRegulator activates the body’s natural inflammatory reflex to produce a potent systemic anti-inflammatory effect and resulting in dampened inflammation and improved clinical signs and symptoms.

"We see the medically regulated iPad app as a key enabler of this product."

The Microregulator is intended to supplement the natural inflammatory reflex by providing built-in therapy at a reduced cost but with improved safety compared with drugs or biologic solutions.

SetPoint Medical has selected Sagentia to develop the app and to advice on the RF and Bluetooth low-energy interfaces within the system.

Sagentia medical sector manager Dr David Pettigrew said: "With this new device, there is the potential to revolutionise the treatment of chronic inflammatory disease by bringing a real new alternative to traditional drug-based therapy.

"We see the medically regulated iPad app as a key enabler of this product and the Sagentia team is proud to contribute our experience in wireless systems engineering and medically-regulated App development to the project," Dr Pettigrew said.

The new implanted device has the potential to offer a new and less expensive treatment option for patients suffering from chronic inflammatory diseases and also help reduce costs by up to 75%.

In addition, the device can last up to ten years, replacing the need for routine injections or pills and reducing the risks associated with current treatments.

SetPoint Medical has received $27m in financing in August for the development programme that is due to continue through 2014.

The company will conduct clinical trials for the device in late-2014 or early 2015.